Pfizer and Ada Health Inc. To Launch Nationwide Online COVID-19 Care Journey
The platform is designed to reduce barriers to care for patients with COVID-19.
Ada Health Inc., a global digital health company, announced the launch of its first digital condition-based care journey, designed to help people understand if they meet current criteria for progression to severe COVID-19 and connect with a health care provider for evaluation of their COVID symptoms and treatment options.
Almost 200 million Americans have one or more risk factors, such as being 50 or older, being pregnant, a smoker, overweight or having certain common medical conditions–such as diabetes or asthma that puts them at high risk of progression to severe COVID. However, many people are not aware of their increased risk. COVID remains the third leading cause of death in the US, currently causing an average of over 400 deaths a day.
The COVID-19 Care Journey is an online platform operated by Ada and developed in partnership with Pfizer. The platform hosts an independent telehealth and ePharmacy provider option. The care journey allows users to:
Continue reading this story here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
